The concept of the “magic bullet”, a medicine designed to hit a specific biological target, was pioneered by Paul Ehrlich, the father of chemotherapy, some 100 years ago. Building on Ehrlich's vision, we have endeavoured to showcase not only how targeted PtIV prodrugs may be exploited to reduce systemic toxicities associated with modern-day chemotherapeutics, including classical PtII drugs, but also how these prodrugs may overcome resistance issues that have plagued many chemotherapeutic regimes. A summary of advances in this field over the past decade is provided, with an emphasis on PtIV prodrugs that target not only DNA but also enzymes, proteins, peptides and hormones. Synthetic strategies for accessing PtIV chemistry are also provided.
CITATION STYLE
Kenny, R. G., Chuah, S. W., Crawford, A., & Marmion, C. J. (2017, March 27). Platinum(IV) Prodrugs – A Step Closer to Ehrlich’s Vision? European Journal of Inorganic Chemistry. Wiley-VCH Verlag. https://doi.org/10.1002/ejic.201601278
Mendeley helps you to discover research relevant for your work.